【康哲药业:9月14日CMS-D001获SLE临床试验批准】康哲药业公告,集团旗下德镁医药自主研发的创新药高选择性TYK2抑制剂CMS-D001此前已获批开展多项适应症药物临床试验。2026年9月11日,CMS-D001获得NMPA签发的系统性红斑狼疮适应症药物临床试验批准通知书,并于2026年9月14日收到;集团正积极准备开展相关临床试验工作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.